Insights

Innovative Diagnostic Tools Octave's development of the industry’s first multivariate blood test for Multiple Sclerosis and their expansion into Parkinson’s disease diagnostics presents significant opportunities for healthcare providers and clinics seeking advanced biomarker solutions for neurodegenerative diseases.

Expanding Market Reach With recent collaborations and substantial grants from leading foundations like The Michael J. Fox Foundation, Octave is positioned to accelerate adoption of its precision medicine platform, creating potential sales channels in neurology clinics, research institutions, and pharmaceutical partners.

Technology-Driven Care The company's multimodal Precision Care Solution, integrating biomarker testing, MRI analytics, and real-time patient management, offers a comprehensive care platform appealing to healthcare organizations aiming to enhance patient monitoring and personalized treatment strategies.

Strategic Funding and Partnerships Recent investments from Hikma Ventures and prominent research grants indicate strong industry interest and validation, opening opportunities for joint ventures, licensing deals, and expanded distribution channels across neurology and biotech markets.

Recognition and Innovation Being recognized as a finalist in Fast Company’s 2023 Innovation by Design Awards highlights Octave’s innovative edge, making it a compelling partner for organizations looking to collaborate on cutting-edge neurodegenerative disease diagnostics and care solutions.

Similar companies to Octave

Octave Tech Stack

Octave uses 8 technology products and services including AppNexus, Verizon Media, cdnjs, and more. Explore Octave's tech stack below.

  • AppNexus
    Advertising
  • Verizon Media
    Advertising
  • cdnjs
    Content Delivery Network
  • Google BigQuery
    Data Warehousing
  • StackAdapt
    Demand Side Platforms
  • JSON-LD
    Javascript Frameworks
  • Pardot
    Marketing
  • Elementor
    Page Builders

Media & News

Octave's Email Address Formats

Octave uses at least 1 format(s):
Octave Email FormatsExamplePercentage
FLast@octavebio.comJDoe@octavebio.com
95%
FirstL@octavebio.comJohnD@octavebio.com
2%
Last@octavebio.comDoe@octavebio.com
2%
First@octavebio.comJohn@octavebio.com
1%

Frequently Asked Questions

Where is Octave's headquarters located?

Minus sign iconPlus sign icon
Octave's main headquarters is located at Menlo Ave, Menlo Park, California 94025, US. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Octave's stock symbol?

Minus sign iconPlus sign icon
Octave is a publicly traded company; the company's stock symbol is OCTAVE.BO.

What is Octave's official website and social media links?

Minus sign iconPlus sign icon
Octave's official website is octavebio.com and has social profiles on LinkedInCrunchbase.

What is Octave's SIC code NAICS code?

Minus sign iconPlus sign icon
Octave's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Octave have currently?

Minus sign iconPlus sign icon
As of October 2025, Octave has approximately 87 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Cfo: M. K.Chief Revenue Officer (cro): J. E.Chief Access Officer: D. S. L.. Explore Octave's employee directory with LeadIQ.

What industry does Octave belong to?

Minus sign iconPlus sign icon
Octave operates in the Biotechnology Research industry.

What technology does Octave use?

Minus sign iconPlus sign icon
Octave's tech stack includes AppNexusVerizon MediacdnjsGoogle BigQueryStackAdaptJSON-LDPardotElementor.

What is Octave's email format?

Minus sign iconPlus sign icon
Octave's email format typically follows the pattern of FLast@octavebio.com. Find more Octave email formats with LeadIQ.

How much funding has Octave raised to date?

Minus sign iconPlus sign icon
As of October 2025, Octave has raised $46M in funding. The last funding round occurred on Dec 17, 2020 for $32M.

When was Octave founded?

Minus sign iconPlus sign icon
Octave was founded in 2014.

Octave

Biotechnology ResearchUnited States51-200 Employees

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave  is currently collaborating with leading clinics, payers, and pharma companies across the country.

Section iconCompany Overview

Headquarters
Menlo Ave, Menlo Park, California 94025, US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
OCTAVE.BO
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $46M

    Octave has raised a total of $46M of funding over 2 rounds. Their latest funding round was raised on Dec 17, 2020 in the amount of $32Mas a Series B.

  • $25M$50M

    Octave's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $46M

    Octave has raised a total of $46M of funding over 2 rounds. Their latest funding round was raised on Dec 17, 2020 in the amount of $32Mas a Series B.

  • $25M$50M

    Octave's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.